InvestSMART

PYC Therapeutics Limited (ASX:PYC)

ALERT: Price-sensitive ASX Announcement for PYC
Current share price for PYC : $2.235 0.62 (38.39%)+
Announcement
Release
21 Jul 2026 8:32AM
Price at Release
$1.615
Full Release
download
Summary
PYC Therapeutics Limited, an Australian precision medicine company, announced significant progress in its ADOA program with the investigational drug PYC-001. Recent studies in non-human primates and ongoing Phase 1/2 clinical trials in humans have shown that PYC-001 increases OPA1 protein expression in the retina and improves visual acuity in patients with Autosomal Dominant Optic Atrophy (ADOA). This breakthrough supports extending the dosing interval of PYC-001 beyond four months. The favorable safety profile of PYC-001 and its potential applicability to other eye diseases are key highlights. PYC Therapeutics is also exploring PYC-001 in pre-clinical models of glaucoma, with plans for future Phase 2 studies.
Key Points
  • PYC Therapeutics advances ADOA program with drug PYC-001.
  • PYC-001 shows increased OPA1 expression and improved visual acuity in trials.
  • PYC-001's safety profile supports extending dosing intervals beyond four months.
  • Company explores PYC-001's potential in other eye diseases, including glaucoma.
  • Phase 1/2 trials in humans complement non-human primate study findings.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.